All patients receiving highest dose had significant T cell responses that correlated with significant reduction in risk of relapse.
A vaccine showed potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone surgery, according to a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center. Results were published January 9, 2024 in Nature Medicine. The open-access article is titled “Lymph Node Targeted Amphiphile Vaccine Induces mKRAS-specific T Cells in Minimal Residual Disease-Positive Pancreatic and Colorectal Cancer: The AMPLIFY-201 Trial.” In the trial, patients with pancreatic and colorectal cancer who were considered at high risk of relapse received a maximum of 10 doses of the ELI-002 vaccine targeted toward KRAS G12D and G12R mutations. T cell responses were seen in 84% of all patients and in 100% of those in the two highest dose cohorts, including those who received the recommended Phase II dose of 10 mg.